166 related articles for article (PubMed ID: 37879236)
21. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
23. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.
Nies M; Vassilopoulou-Sellin R; Bassett RL; Yedururi S; Zafereo ME; Cabanillas ME; Sherman SI; Links TP; Waguespack SG
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1683-e1697. PubMed ID: 33382403
[TBL] [Abstract][Full Text] [Related]
24. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
[TBL] [Abstract][Full Text] [Related]
25. Application of molecular biology of differentiated thyroid cancer for clinical prognostication.
Marotta V; Sciammarella C; Colao A; Faggiano A
Endocr Relat Cancer; 2016 Nov; 23(11):R499-R515. PubMed ID: 27578827
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
27. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract][Full Text] [Related]
28. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
31. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
32. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
[TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
34. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
[TBL] [Abstract][Full Text] [Related]
35. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
38. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
39. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
40. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
